Intuitive Surgical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets da Vinci surgical systems, and related instruments and accessories in the United States and internationally. The company's da Vinci Surgical System include surgeon's consoles, patient-side carts, 3-D HD vision systems, skills simulators, da Vinci Xi integrated table motions, and Firefly fluorescence imaging products that enable surgeons to perform various surgical procedures, including gynecologic, urologic, general, cardiothoracic, and head and neck surgical procedures. It also manufactures EndoWrist instruments, such as forceps, scissors, electrocautery tools, scalpels, and other surgical tools, which incorporate wrist joints for natural dexterity for various surgical procedures; and provides SimNow, a cloud-enabled simulation platform, which allows surgeons to learn and practice their surgical skills; Iris, an augmented reality imaging product for use in kidney procedures; and Intuitive Cloud that enables proactive monitoring and software updates. In addition, the company offers EndoWrist Stapler, a wristed stapling instrument for resection, transection, and creation of anastomoses; EndoWrist One Vessel Sealers that are wristed single-use instruments for bipolar coagulation and mechanical transection of vessels up to 7mm in diameter and tissue bundles that fit in the jaws of the instrument; E-100 generator, an electrosurgical generator; SureForm 45 Curved-Tip stapler; and SynchroSeal for sealing and transection with a single pedal press. Additionally, the company sells various accessories comprising sterile drapes for ensuring sterile field during surgery; and vision products that include replacement 3D stereo endoscopes, camera heads, light guides, and other items that facilitate the use of the da Vinci Surgical System, as well as Ion endoluminal system for biopsies. Intuitive Surgical, Inc. was founded in 1995 and is headquartered in Sunnyvale, California.
IPO Year: 2000
Exchange: NASDAQ
Website: intuitive.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2024 | $522.00 → $650.00 | Equal-Weight → Overweight | Morgan Stanley |
| 8/2/2024 | $380.00 → $510.00 | Neutral → Buy | Redburn Atlantic |
| 7/10/2024 | $462.00 → $512.00 | Buy | Citigroup |
| 5/30/2024 | $500.00 | Buy | Goldman |
| 11/17/2023 | $318.00 | Buy | HSBC Securities |
| 7/19/2023 | $377.00 | Outperform | Robert W. Baird |
| 4/19/2023 | $240.00 → $270.00 | In-line | Evercore ISI |
| 4/19/2023 | $305.00 → $317.00 | Buy | Citigroup |
| 4/19/2023 | $284.00 → $313.00 | Buy | BTIG Research |
| 4/19/2023 | $285.00 → $315.00 | Buy | Stifel |
4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)
4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)
4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)
4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)
4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)
4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)
4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)
4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)
4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)
4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)
SC 13G/A - INTUITIVE SURGICAL INC (0001035267) (Subject)
SC 13G/A - INTUITIVE SURGICAL INC (0001035267) (Subject)
SC 13G/A - INTUITIVE SURGICAL INC (0001035267) (Subject)
SC 13G/A - INTUITIVE SURGICAL INC (0001035267) (Subject)
SC 13G/A - INTUITIVE SURGICAL INC (0001035267) (Subject)
SC 13G/A - INTUITIVE SURGICAL INC (0001035267) (Subject)
SC 13G/A - INTUITIVE SURGICAL INC (0001035267) (Subject)
SC 13G/A - INTUITIVE SURGICAL INC (0001035267) (Subject)
SC 13G/A - INTUITIVE SURGICAL INC (0001035267) (Subject)
SAN CARLOS, Calif., Oct. 28, 2024 /PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced the addition of Deborah Kilpatrick, Ph.D., former CEO of Evidation Health and co-founder of MedtechWomen, as a Venture Partner. Kilpatrick earned her Ph.D. from Georgia Tech in mechanical engineering with a focus in bioengineering and a minor in applied mathematics. Most recently, she was the CEO and Executive Chair of the Board at Evidation Health, a technology company that pioneered th
Carl J. St. Bernard Appointed as Chief Executive Officer Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures using Endoportal ControlTM to bring the precision and control of direct surgical access to catheter-based interventions, announced today that it has exited stealth mode with a $21 million new round of financing. Sonder Capital was a key participant in the round that included participation from multiple strategic investors. The funding will be used to support the company's upcoming pivotal trial for Pulmonary Embolism and development of additional clinical applications of the Endoportal ControlTM technology. "For decades, the
Co-founders and industry luminaries Dr. Fred Moll and Jay Watkins will assume the newly created role of Co-chair as firm closes its latest fund, Futures II Sonder Capital, a leading venture capital firm focused on identifying teams and technologies that will transform healthcare, today announced the appointment of firm Co-founder Kate Garrett as Managing Partner. In this pivotal role, Garrett will spearhead Sonder's next phase of growth as the firm closes Sonder Futures II, its second early stage fund. With Garrett becoming Managing Partner, Sonder Co-founders and industry luminaries Fred Moll, M.D. and Jay Watkins will maintain their roles as partners and assume the newly created posit
SUNNYVALE, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced the appointment of Sreelakshmi Kolli, executive vice president and chief digital officer at Align Technology, to its board of directors, effective Oct. 27, 2023. "Sree has deep expertise in applying technology to transform industries, enable business growth and drive strategy," said Intuitive CEO Gary Guthart. "We look forward to her insights, particularly with respect to digital capabilities and meaningful customer experiences, as we continue to advance what's possible in minimally invasive care."
SUNNYVALE, Calif., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced the appointment of Yong-Bum Choi as General Manager for South Korea, where he will direct business strategy and operations for the company. "South Korea remains a key market for minimally invasive care, and we are confident that Yong-Bum Choi will help Intuitive strengthen its position in the country's healthcare market and our continued collaboration with South Korea hospitals and surgeons," said Intuitive President of South Korea and Japan Kazuhiro Takizawa. "Choi's extensive experience in both th
SUNNYVALE, Calif., April 26, 2021 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced the appointment of Dr. Monica P. Reed, a former AdventHealth executive, to its board of directors effective April 22, 2021. "Dr. Reed brings decades of leadership insight, experience, and accomplishments in hospital and health system administration that will complement our existing board," said Intuitive CEO Gary Guthart. "We look forward to her contributions as we continue to improve how we serve our surgeon, hospital, and healthcare system customers in this rapidly evolving healthcare environme
SUNNYVALE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced certain unaudited preliminary fourth quarter and full year 2024 financial results ahead of its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. Financial and Operational Highlights Fourth quarter 2024 worldwide da Vinci procedures grew approximately 18% compared with the fourth quarter of 2023.Full year 2024 worldwide da Vinci procedures grew approximately 17% compared with 2023. The Company expects worldwide da Vinci procedures to i
SUNNYVALE, Calif., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced executive leadership promotions in support of the company's continued global growth in pursuit of its mission to advance minimally invasive care. Henry Charlton has been promoted to the role of executive vice president and chief commercial and marketing officer. A 21-year Intuitive veteran, Charlton has served in key leadership roles across the business, including the U.S., European, APAC, and global distribution and commercial organizations, regional marketing, global customer services and comm
Analysis included 230 studies—a mix of randomized, prospective, and database research SUNNYVALE, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:ISRG) The peer-reviewed Annals of Surgery published a meta-analysis of 30-day surgical outcomes across seven oncological surgical procedures, comparing robotic, laparoscopic, and open surgical approaches. The study covered a 12-year timeframe and analyzed 230 studies from 22 countries: 34 randomized controlled trials, 74 prospective studies, and 122 database reviews. Each surgical approach represented more than a million procedures. The meta-analysis, conducted by scientists from Intuitive and Massachusetts General Hospital, demonstrated mult
SAN CARLOS, Calif., Oct. 28, 2024 /PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced the addition of Deborah Kilpatrick, Ph.D., former CEO of Evidation Health and co-founder of MedtechWomen, as a Venture Partner. Kilpatrick earned her Ph.D. from Georgia Tech in mechanical engineering with a focus in bioengineering and a minor in applied mathematics. Most recently, she was the CEO and Executive Chair of the Board at Evidation Health, a technology company that pioneered th
SUNNYVALE, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended September 30, 2024. Q3 Highlights Worldwide da Vinci procedures grew approximately 18% compared with the third quarter of 2023.The Company placed 379 da Vinci surgical systems, compared with 312 in the third quarter of 2023. The third quarter 2024 da Vinci surgical system placements included 110 da Vinci 5 systems.The Company grew its da Vinci surgical system installed base to 9,539 systems as of Septemb
Carl J. St. Bernard Appointed as Chief Executive Officer Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures using Endoportal ControlTM to bring the precision and control of direct surgical access to catheter-based interventions, announced today that it has exited stealth mode with a $21 million new round of financing. Sonder Capital was a key participant in the round that included participation from multiple strategic investors. The funding will be used to support the company's upcoming pivotal trial for Pulmonary Embolism and development of additional clinical applications of the Endoportal ControlTM technology. "For decades, the
Neptune Medical, a leader in medical device innovation, today announced the successful spinout of its subsidiary, Jupiter Endovascular, following the completion of a $97 million Series D financing. Sonder Capital and Olympus Corporation of the Americas were significant participants in this round, along with investments from other existing and new investors. This financing will strengthen Neptune Medical as a gastrointestinal-focused company expanding into robotics for GI disease, as evidenced by the recent appointment of medical robotics pioneer Dr. Fred Moll as Chairman of the Board. It will also enable Jupiter Endovascular to focus on its novel endovascular technology platform. "Neptu
SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced today that Intuitive President David J. Rosa has been appointed to the Company's Board of Directors, effective July 24, 2024. Rosa joins Intuitive CEO Gary S. Guthart, PhD, as one of two Intuitive executives on the Company's Board. As president, Rosa manages Intuitive's core business operations, which is balanced by Guthart's focus on enterprise strategy and corporate functions. Together, Rosa and Guthart represent more than 50 years of Intuitive leadership. Intuitive appointed Rosa as president in May 2
SUNNYVALE, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended June 30, 2024. Q2 Highlights Worldwide da Vinci procedures grew approximately 17% compared with the second quarter of 2023.The Company placed 341 da Vinci surgical systems, compared with 331 in the second quarter of 2023. The second quarter 2024 da Vinci surgical system placements included 70 da Vinci 5 systems.The Company grew its da Vinci surgical system installed base to 9,203 systems as of June 30, 2024, an increase of 14%
SUNNYVALE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced today that the U.S. Food and Drug Administration (FDA) cleared a labeling revision for da Vinci X and Xi specific to radical prostatectomy. This clearance was based on real-world evidence (RWE) collected from 2007 to 2014 that demonstrates overall five- to 10-year survival following robotic-assisted radical prostatectomy is similar to non-robotic radical prostatectomy. In a public-private collaboration, Intuitive worked with the FDA, healthcare analytics company Aetion, and the National Evaluation Syste
Morgan Stanley upgraded Intuitive Surgical from Equal-Weight to Overweight and set a new price target of $650.00 from $522.00 previously
Redburn Atlantic upgraded Intuitive Surgical from Neutral to Buy and set a new price target of $510.00 from $380.00 previously
Citigroup reiterated coverage of Intuitive Surgical with a rating of Buy and set a new price target of $512.00 from $462.00 previously
Goldman initiated coverage of Intuitive Surgical with a rating of Buy and set a new price target of $500.00
HSBC Securities initiated coverage of Intuitive Surgical with a rating of Buy and set a new price target of $318.00
Robert W. Baird initiated coverage of Intuitive Surgical with a rating of Outperform and set a new price target of $377.00
Evercore ISI reiterated coverage of Intuitive Surgical with a rating of In-line and set a new price target of $270.00 from $240.00 previously
Citigroup reiterated coverage of Intuitive Surgical with a rating of Buy and set a new price target of $317.00 from $305.00 previously
BTIG Research reiterated coverage of Intuitive Surgical with a rating of Buy and set a new price target of $313.00 from $284.00 previously
Stifel reiterated coverage of Intuitive Surgical with a rating of Buy and set a new price target of $315.00 from $285.00 previously
SUNNYVALE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced certain unaudited preliminary fourth quarter and full year 2024 financial results ahead of its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. Financial and Operational Highlights Fourth quarter 2024 worldwide da Vinci procedures grew approximately 18% compared with the fourth quarter of 2023.Full year 2024 worldwide da Vinci procedures grew approximately 17% compared with 2023. The Company expects worldwide da Vinci procedures to i
SUNNYVALE, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended September 30, 2024. Q3 Highlights Worldwide da Vinci procedures grew approximately 18% compared with the third quarter of 2023.The Company placed 379 da Vinci surgical systems, compared with 312 in the third quarter of 2023. The third quarter 2024 da Vinci surgical system placements included 110 da Vinci 5 systems.The Company grew its da Vinci surgical system installed base to 9,539 systems as of Septemb
SUNNYVALE, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended June 30, 2024. Q2 Highlights Worldwide da Vinci procedures grew approximately 17% compared with the second quarter of 2023.The Company placed 341 da Vinci surgical systems, compared with 331 in the second quarter of 2023. The second quarter 2024 da Vinci surgical system placements included 70 da Vinci 5 systems.The Company grew its da Vinci surgical system installed base to 9,203 systems as of June 30, 2024, an increase of 14%
SUNNYVALE, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended March 31, 2024. Q1 Highlights Worldwide da Vinci procedures grew approximately 16% compared with the first quarter of 2023.The Company placed 313 da Vinci surgical systems, compared with 312 in the first quarter of 2023.The Company grew its da Vinci surgical system installed base to 8,887 systems as of March 31, 2024, an increase of 14% compared with 7,779 as of the end of the first quarter of 2023.First quarter 2024 revenue of $1.89 billion
SUNNYVALE, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended December 31, 2023. Q4 Highlights Worldwide da Vinci procedures grew approximately 21% compared with the fourth quarter of 2022.The Company placed 415 da Vinci surgical systems, compared with 369 in the fourth quarter of 2022.The Company grew its da Vinci surgical system installed base to 8,606 systems as of December 31, 2023, an increase of 14% compared with 7,544 as of the end of the fourth quarter of 2022.Four
SUNNYVALE, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced certain unaudited preliminary fourth quarter and full year 2023 financial results ahead of its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. Financial and Operational Highlights Fourth quarter 2023 worldwide da Vinci procedures grew approximately 21% compared with the fourth quarter of 2022. The comparative fourth quarter of 2022 reflected a resurgence of COVID-19 in China, which negatively impacted procedure volumes in the region.Full year 2
SUNNYVALE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended September 30, 2023. Q3 Highlights Worldwide da Vinci procedures grew approximately 19% compared with the third quarter of 2022. The compound annual growth rate between the third quarter of 2019 and the third quarter of 2023 was approximately 17%.The Company placed 312 da Vinci surgical systems, compared with 305 in the third quarter of 2022.The Company grew its da Vinci surgical system installed base to 8,285 systems as of September 30, 2023,
SUNNYVALE, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended June 30, 2023. Q2 Highlights Worldwide da Vinci procedures grew approximately 22% compared with the second quarter of 2022. During the second quarter of 2022, the Company's procedure volumes were negatively impacted by COVID-19 cases and increased hospitalizations and government interventions impacting parts of Asia, particularly China. The compound annual growth rate between the second quarter of 2019 and the second quarter of 2023 was approx
SUNNYVALE, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended March 31, 2023. Q1 Highlights Worldwide da Vinci procedures grew approximately 26% compared with the first quarter of 2022. The first quarter of 2023 reflected continued disruptions from COVID-19 in China, which negatively impacted procedure volumes in January. The first quarter of 2022 also reflected COVID-19 disruptions in January in the U.S. and, in the latter part of the quarter, in Asia, which negatively impacted procedure volumes. The c
SUNNYVALE, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended December 31, 2022. Q4 Highlights Worldwide da Vinci procedures grew approximately 18% compared with the fourth quarter of 2021. The fourth quarter of 2022 reflected a resurgence in COVID-19 in China, which negatively impacted procedure volumes in the region. The fourth quarter of 2021 also reflected COVID-19 disruptions later in the quarter in the U.S. and Europe, which impacted our procedures. The compound annual growth rate betwe
8-K - INTUITIVE SURGICAL INC (0001035267) (Filer)
8-K - INTUITIVE SURGICAL INC (0001035267) (Filer)
144 - INTUITIVE SURGICAL INC (0001035267) (Subject)
10-Q - INTUITIVE SURGICAL INC (0001035267) (Filer)
8-K - INTUITIVE SURGICAL INC (0001035267) (Filer)
8-K - INTUITIVE SURGICAL INC (0001035267) (Filer)
S-8 - INTUITIVE SURGICAL INC (0001035267) (Filer)
10-Q - INTUITIVE SURGICAL INC (0001035267) (Filer)
8-K - INTUITIVE SURGICAL INC (0001035267) (Filer)
SD - INTUITIVE SURGICAL INC (0001035267) (Filer)